Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 331 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Relapsed Acute Myeloid Leukemia - Pipeline Review, H1 2015’, provides an overview of the Relapsed Acute Myeloid Leukemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsed Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Relapsed Acute Myeloid Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Relapsed Acute Myeloid Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Relapsed Acute Myeloid Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Relapsed Acute Myeloid Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Relapsed Acute Myeloid Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Relapsed Acute Myeloid Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Relapsed Acute Myeloid Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for Relapsed Acute Myeloid Leukemia - Overview 10
Pipeline Products for Relapsed Acute Myeloid Leukemia - Comparative Analysis 11
Relapsed Acute Myeloid Leukemia - Therapeutics under Development by Companies 12
Relapsed Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 17
Relapsed Acute Myeloid Leukemia - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Relapsed Acute Myeloid Leukemia - Products under Development by Companies 21
Relapsed Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 25
Relapsed Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 26
4SC AG 26
AbbVie Inc. 27
Actinium Pharmaceuticals, Inc. 28
Agios Pharmaceuticals, Inc. 29
Amgen Inc. 30
Array BioPharma Inc. 31
Astellas Pharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
AVEO Pharmaceuticals, Inc. 35
Boehringer Ingelheim GmbH 36
Bristol-Myers Squibb Company 37
Calithera Biosciences, Inc. 38
Celgene Corporation 39
Conkwest, Inc. 40
Cornerstone Pharmaceuticals, Inc. 41
CTI BioPharma Corp. 42
Daiichi Sankyo Company, Limited 43
Eisai Co., Ltd. 44
EpiZyme, Inc. 45
Exelixis, Inc. 46
F. Hoffmann-La Roche Ltd. 47
Fujifilm Corporation 48
GlaxoSmithKline plc 49
Igenica Biotherapeutics, Inc. 50
Incyte Corporation 51
Jiangsu Hansoh Pharmaceutical Co., Ltd. 52
JW Pharmaceutical Corporation 53
Karyopharm Therapeutics, Inc. 54
Kyowa Hakko Kirin Co., Ltd. 55
Les Laboratoires Servier SAS 56
MacroGenics, Inc. 57
Merck & Co., Inc. 58
Millennium Pharmaceuticals, Inc. 59
Novartis AG 60
Oxford BioTherapeutics Ltd 61
Plexxikon Inc. 62
Polaris Pharmaceuticals, Inc. 63
Seattle Genetics, Inc. 64
Sunesis Pharmaceuticals, Inc. 65
Synta Pharmaceuticals Corp. 66
Tolero Pharmaceuticals, Inc. 67
Verastem, Inc. 68
Relapsed Acute Myeloid Leukemia - Therapeutics Assessment 69
Assessment by Monotherapy Products 69
Assessment by Combination Products 70
Assessment by Target 71
Assessment by Mechanism of Action 75
Assessment by Route of Administration 78
Assessment by Molecule Type 80
Drug Profiles 82
4SC-202 - Drug Profile 82
AG-120 - Drug Profile 84
AG-221 - Drug Profile 86
alvocidib hydrochloride - Drug Profile 89
AMG-232 - Drug Profile 90
AT-9283 - Drug Profile 91
BI-836858 - Drug Profile 93
binimetinib - Drug Profile 94
bortezomib - Drug Profile 99
brentuximab vedotin - Drug Profile 104
cabozantinib s-malate - Drug Profile 109
cafusertib hydrochloride - Drug Profile 112
CB-839 - Drug Profile 113
Cell Therapy to Target CD123 for Relapsed and Refractory Acute Myeloid Leukemia - Drug Profile 114
Cell Therapy to Target CD33 for Acute Myeloid Leukemia - Drug Profile 115
Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 116
CPI-613 - Drug Profile 117
crenolanib besylate - Drug Profile 119
CST-101 - Drug Profile 121
CWP-291 - Drug Profile 123
DFP-10917 - Drug Profile 125
DS-3032 - Drug Profile 126
elesclomol - Drug Profile 127
EPZ-5676 - Drug Profile 129
erlotinib hydrochloride - Drug Profile 131
FF-10501 - Drug Profile 134
ficlatuzumab - Drug Profile 135
FLX-925 - Drug Profile 137
gilteritinib fumarate - Drug Profile 138
GO-2032c - Drug Profile 139
GSK-2879552 - Drug Profile 140
GSK-525762 - Drug Profile 141
huCART19 - Drug Profile 142
IGN-523 - Drug Profile 143
ilorasertib - Drug Profile 144
imatinib mesylate - Drug Profile 146
indisulam - Drug Profile 148
Iomab-B - Drug Profile 149
KHK-2823 - Drug Profile 151
lenalidomide - Drug Profile 152
LGH-447 - Drug Profile 156
MGD-006 - Drug Profile 157
MK-2206 - Drug Profile 158
OX-001 - Drug Profile 161
pegargiminase - Drug Profile 162
PLX-3397 - Drug Profile 165
quizartinib dihydrochloride - Drug Profile 167
RG-7775 - Drug Profile 170
ruxolitinib phosphate - Drug Profile 171
S-055746 - Drug Profile 176
selinexor - Drug Profile 177
selumetinib sulfate - Drug Profile 181
Small Molecules to Inhibit MDM2 for Oncology - Drug Profile 184
TAK-659 - Drug Profile 185
TEN-010 - Drug Profile 186
tigecycline - Drug Profile 187
tosedostat - Drug Profile 188
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 190
ulocuplumab - Drug Profile 192
venetoclax - Drug Profile 194
vorinostat - Drug Profile 197
vosaroxin - Drug Profile 201
VS-4718 - Drug Profile 203
Relapsed Acute Myeloid Leukemia - Recent Pipeline Updates 204
Relapsed Acute Myeloid Leukemia - Dormant Projects 316
Relapsed Acute Myeloid Leukemia - Discontinued Products 317
Relapsed Acute Myeloid Leukemia - Product Development Milestones 318
Featured News & Press Releases 318
Appendix 326
Methodology 326
Coverage 326
Secondary Research 326
Primary Research 326
Expert Panel Validation 326
Contact Us 326
Disclaimer 327

List of Tables
Number of Products under Development for Relapsed Acute Myeloid Leukemia, H1 2015 14
Number of Products under Development for Relapsed Acute Myeloid Leukemia - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Development by Companies, H1 2015 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Relapsed Acute Myeloid Leukemia - Pipeline by 4SC AG, H1 2015 30
Relapsed Acute Myeloid Leukemia - Pipeline by AbbVie Inc., H1 2015 31
Relapsed Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 32
Relapsed Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals, Inc., H1 2015 33
Relapsed Acute Myeloid Leukemia - Pipeline by Amgen Inc., H1 2015 34
Relapsed Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc., H1 2015 35
Relapsed Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc., H1 2015 36
Relapsed Acute Myeloid Leukemia - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 37
Relapsed Acute Myeloid Leukemia - Pipeline by AstraZeneca PLC, H1 2015 38
Relapsed Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 39
Relapsed Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H1 2015 40
Relapsed Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H1 2015 41
Relapsed Acute Myeloid Leukemia - Pipeline by Calithera Biosciences, Inc., H1 2015 42
Relapsed Acute Myeloid Leukemia - Pipeline by Celgene Corporation, H1 2015 43
Relapsed Acute Myeloid Leukemia - Pipeline by Conkwest, Inc., H1 2015 44
Relapsed Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 45
Relapsed Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp., H1 2015 46
Relapsed Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 47
Relapsed Acute Myeloid Leukemia - Pipeline by Eisai Co., Ltd., H1 2015 48
Relapsed Acute Myeloid Leukemia - Pipeline by EpiZyme, Inc., H1 2015 49
Relapsed Acute Myeloid Leukemia - Pipeline by Exelixis, Inc., H1 2015 50
Relapsed Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 51
Relapsed Acute Myeloid Leukemia - Pipeline by Fujifilm Corporation, H1 2015 52
Relapsed Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline plc, H1 2015 53
Relapsed Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics, Inc., H1 2015 54
Relapsed Acute Myeloid Leukemia - Pipeline by Incyte Corporation, H1 2015 55
Relapsed Acute Myeloid Leukemia - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2015 56
Relapsed Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corporation, H1 2015 57
Relapsed Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 58
Relapsed Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 59
Relapsed Acute Myeloid Leukemia - Pipeline by Les Laboratoires Servier SAS, H1 2015 60
Relapsed Acute Myeloid Leukemia - Pipeline by MacroGenics, Inc., H1 2015 61
Relapsed Acute Myeloid Leukemia - Pipeline by Merck & Co., Inc., H1 2015 62
Relapsed Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 63
Relapsed Acute Myeloid Leukemia - Pipeline by Novartis AG, H1 2015 64
Relapsed Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H1 2015 65
Relapsed Acute Myeloid Leukemia - Pipeline by Plexxikon Inc., H1 2015 66
Relapsed Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 67
Relapsed Acute Myeloid Leukemia - Pipeline by Seattle Genetics, Inc., H1 2015 68
Relapsed Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 69
Relapsed Acute Myeloid Leukemia - Pipeline by Synta Pharmaceuticals Corp., H1 2015 70
Relapsed Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 71
Relapsed Acute Myeloid Leukemia - Pipeline by Verastem, Inc., H1 2015 72
Assessment by Monotherapy Products, H1 2015 73
Assessment by Combination Products, H1 2015 74
Number of Products by Stage and Target, H1 2015 76
Number of Products by Stage and Mechanism of Action, H1 2015 80
Number of Products by Stage and Route of Administration, H1 2015 83
Number of Products by Stage and Molecule Type, H1 2015 85
Relapsed Acute Myeloid Leukemia Therapeutics - Recent Pipeline Updates, H1 2015 208
Relapsed Acute Myeloid Leukemia - Dormant Projects, H1 2015 320
Relapsed Acute Myeloid Leukemia - Discontinued Products, H1 2015 321